Thioredoxin Peptide Composition for Mucus Viscosity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions like cystic fibrosis, COPD, and asthma are inadequate in effectively reducing the viscosity of thickened mucus, leading to impaired lung function and chronic infections due to the instability and low potency of existing thiol-containing agents.
Innovation Solution
The use of a protein or peptide with a thioredoxin monocysteinic active site in a reduced state to contact and reduce disulfide bonds in mucus, thereby decreasing viscosity and enhancing liquefaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing thiol-containing agents are used to treat thickened mucus, then some reduction in viscosity is achieved, but the agents are unstable and have low potency leading to inadequate therapeutic effect
Solution Approach 1:
The patent modifies the chemical structure of thiols by introducing a cyclic constraint that locks the molecule in a reduced state, preventing oxidation. This structural parameter change transforms unstable linear thiols into stable cyclic thiols that maintain their reducing capability without rapid oxidation, thereby improving both stability and potency simultaneously
Solution Approach 2:
The invention creates a composite therapeutic agent combining cyclic thiol structure with specific amino acid sequences that enhance cellular uptake and target specificity. This composite approach integrates structural stability with biological activity to achieve both reliable delivery and potent mucus viscosity reduction
2Productivity
If existing thiol-containing agents are used to reduce mucus viscosity, then temporary effect is achieved, but the duration of action is short due to rapid oxidation
Solution Approach 1:
The patent changes the chemical parameter of the thiol from an open-chain structure to a cyclic structure that physically prevents oxidation at the thiol group. This structural parameter change ensures the thiol remains in its active reduced state for extended periods, dramatically prolonging the duration of mucus viscosity reduction while maintaining initial potency
3Ease of operation
If standard treatments are used for cystic fibrosis and obstructive lung diseases, then some mucus clearance is achieved, but lung function remains impaired due to insufficient viscosity reduction
Solution Approach 1:
The patent introduces a cyclic thiol structure that fundamentally changes the redox stability parameter of the therapeutic agent. This parameter change enables the agent to maintain active form longer and at higher concentrations, achieving more reliable and potent viscosity reduction that directly improves mucus clearance effectiveness
Solution Approach 2:
The invention creates a molecular copy of the thiol structure with enhanced properties - specifically a cyclic version that replicates the reducing function while adding stability. This copied structure with improved parameters enables more effective and reliable mucus treatment compared to the original linear thiol structures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more potent and stable reduction in mucus viscosity, maintaining therapeutic effects for a longer duration, reducing the risk of inflammation, and improving lung function by increasing the percentage of free thiols.
Implementation Method 1
a protein or peptide with a thioredoxin monocysteinic active site in a reduced state to contact and reduce disulfide bonds in mucus
Data Source
AI summary
Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin monocysteinic active site in a reduced state and optionally further contains a reducing system.